JP2024516962A5 - - Google Patents

Info

Publication number
JP2024516962A5
JP2024516962A5 JP2023563876A JP2023563876A JP2024516962A5 JP 2024516962 A5 JP2024516962 A5 JP 2024516962A5 JP 2023563876 A JP2023563876 A JP 2023563876A JP 2023563876 A JP2023563876 A JP 2023563876A JP 2024516962 A5 JP2024516962 A5 JP 2024516962A5
Authority
JP
Japan
Prior art keywords
seq
fab
amino acid
acid sequence
sequence described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563876A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516962A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/060236 external-priority patent/WO2022223514A1/en
Publication of JP2024516962A publication Critical patent/JP2024516962A/ja
Publication of JP2024516962A5 publication Critical patent/JP2024516962A5/ja
Pending legal-status Critical Current

Links

JP2023563876A 2021-04-19 2022-04-19 安定性が改善された抗TSLP Fab Pending JP2024516962A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21169183 2021-04-19
EP21169183.7 2021-04-19
PCT/EP2022/060236 WO2022223514A1 (en) 2021-04-19 2022-04-19 An anti-tslp fab with improved stability

Publications (2)

Publication Number Publication Date
JP2024516962A JP2024516962A (ja) 2024-04-18
JP2024516962A5 true JP2024516962A5 (enExample) 2025-05-16

Family

ID=75588042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563876A Pending JP2024516962A (ja) 2021-04-19 2022-04-19 安定性が改善された抗TSLP Fab

Country Status (19)

Country Link
US (1) US20240199730A1 (enExample)
EP (1) EP4326767A1 (enExample)
JP (1) JP2024516962A (enExample)
KR (1) KR20230172508A (enExample)
CN (1) CN117222665A (enExample)
AR (1) AR125379A1 (enExample)
AU (1) AU2022263281A1 (enExample)
BR (1) BR112023021587A2 (enExample)
CA (1) CA3216894A1 (enExample)
CL (1) CL2023003082A1 (enExample)
CO (1) CO2023015286A2 (enExample)
CR (1) CR20230533A (enExample)
EC (1) ECSP23086870A (enExample)
IL (1) IL307651A (enExample)
MX (1) MX2023012266A (enExample)
PH (1) PH12023552762A1 (enExample)
SA (1) SA523451188B1 (enExample)
TW (1) TW202306982A (enExample)
WO (1) WO2022223514A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66646B1 (sr) * 2019-10-28 2025-04-30 Medimmune Ltd Formulacije suvog praška vezujućih antitela za timusni stromalni limfopoetin (tslp) i postupci njihove upotrebe
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2025163008A1 (en) 2024-01-29 2025-08-07 Astrazeneca Ab Compositions of thymic stromal lymphopoietin (tslp) binding fragments and methods of use thereof
USD1126392S1 (en) 2024-05-16 2026-05-12 Astrazeneca Ab Inhaler
US20260034317A1 (en) 2024-05-20 2026-02-05 Medimmune Limited Inhaler and capsule for delivering thymic stromal lymphopoietin (tslp)-binding antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2429544C (en) 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
JP7330896B2 (ja) * 2017-04-12 2023-08-22 アムジェン インコーポレイテッド 抗tslp抗体による喘息治療
JP7331298B2 (ja) * 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合tslp及びその使用
RS66646B1 (sr) * 2019-10-28 2025-04-30 Medimmune Ltd Formulacije suvog praška vezujućih antitela za timusni stromalni limfopoetin (tslp) i postupci njihove upotrebe

Similar Documents

Publication Publication Date Title
WO2024119625A1 (zh) 双链rna的合成方法及rna连接酶在双链rna合成中的应用
CN106086102B (zh) 一种生产反式-4-羟基-l-脯氨酸的工程菌及其构建方法与应用
CN109970858B (zh) Cd22单域抗体、核苷酸序列及试剂盒
JP2025090679A5 (enExample)
WO2015158213A1 (zh) 一种具有高转糖苷活性的β-半乳糖苷酶突变体及其制备方法和应用
CN113754726B (zh) 一种含多肽标签的重组酶及其在医药化学品合成中的应用
CN107641629B (zh) 一种安达喜盐芽孢杆菌耐盐碱基因rdd及其鉴定方法
Kefala et al. Structures of the OmpF porin crystallized in the presence of foscholine‐12
CN105647912A (zh) 抗酸表达盒及其筛选方法
JPWO2023282161A5 (enExample)
JP2023171909A5 (enExample)
CN117486982B (zh) 转运蛋白TdcC在提高L-肌肽的产量中的应用
CN116574750B (zh) 一种提高腈类化合物生物转化效率的腈水合酶重组质粒及其构建方法与应用
JP2001340091A (ja) アミド化合物の製造方法
CN106188251A (zh) 一种免疫球蛋白结合蛋白突变体及其用途
Hostomský et al. Solid-phase assembly of cow colostrum trypsin inhibitor gene
JP2015536347A5 (enExample)
CN111499744A (zh) 一种乳铁蛋白纳米抗体及制备方法、应用
CN102241759A (zh) 一种抑菌性铁蛋白及其制备和应用
CN102965376B (zh) 一种 n-(3-氧化十二烷酰基)-l-同型丝氨酸内酯核酸适体及其筛选方法和应用
CN104474557A (zh) 一种具有抑菌活性的长牡蛎C型凝集素-2(CgCLec-2)重组蛋白的应用
WO2026011786A1 (zh) 一种Patisiran的制备方法
JP2024523166A5 (enExample)
WO2026011783A1 (zh) 一种Givosiran的制备方法
WO2026011787A1 (zh) 一种qpi-1002的制备方法